 |
|
Impetigo
NANCY B. ESTERLY, MD
Departments of Pediatrics and Dermatology
DAVID B. NELSON, MD
Department of Pediatrics
W. MICHAEL DUNNE, JR, PHD
Departments of Pediatrics and Pathology Medical College of Wisconsin Milwaukee, WI 53226
Am J Dis Child. 1991;145(2):125-126.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Sir.—Issues relating to the management of impetigo, a common pediatric problem, continue to be discussed in these pages.1,2 Although orally administered antibiotics have been considered optimal therapy for many years, the advent of a novel topical antibiotic, mupirocin, has prompted several clinical trials comparing the efficacy, compliance, cost, and safety of these two treatment modalities. In many of these trials, erythromycin has been used as the prototypic oral agent.3-6
We recently completed a study of 48 patients with impetigo randomized to receive mupirocin or erythromycin therapy. Twenty-five children received mupirocin and 23, erythromycin. We were interested not only in the comparative efficacy of these drugs, but also in the microbiologic data and antibiotic sensitivities of the bacteria cultured, as recent studies have suggested that Staphylococcus aureus is now the most common cause of impetigo and that a large number of these strains may be resistant to erythromycin.
. . . [Full Text PDF of this Article]
Footnotes
This department of AJDC is reserved for comment, criticism, observation, and discussion of "issues of current concern and importance for children's health." The Editor encourages our readers to express themselves on a variety of topics and issues. Further, we encourage the submission of unique and brief clinical and scientific observations that do not fulfill the criteria for original articles.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
